Cardiomyopathies market set to reach $5.2 billion by 2031

The cardiomyopathies market is set to grow from $1.6 billion in 2021 to $5.2 billion in 2031 across the seven major markets (7MM: USA, 5EU (France, Germany, Italy, Spain, and the UK), and Japan) at a compound annual growth rate (CAGR) of 12.4%.

Data and analytics company GlobalData notes that growth in the USA, 5EU and Japan will largely be driven by late-stage pipeline products.

According to GlobalData’s report, ‘ Cardiomyopathies Market Size and Trend Report, 2021-2031’, cardiomyopathies are most often managed with generic drugs such as beta blockers, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs).